Wu Chou Su

Wu Chou Su publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Wu Chou Su sits on this spectrum.

Wu Chou Su D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Wu Chou Su sits on this spectrum.

Best Publications

• Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

  Jean-Charles Soria;Yuichiro Ohe;Johan Vansteenkiste;Thanyanan Reungwetwattana

  4403
  Citations

• Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

  Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  3555
  Citations

• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

  Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski

  3207
  Citations

• AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

  Pasi A. Jänne;James Chih-Hsin Yang;Dong Wan Kim;David Planchard

  2236
  Citations

• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

  James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  1331
  Citations

• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

  Vincent A. Miller;Vincent A. Miller;Vera Hirsh;Jacques Cadranel;Yuh Min Chen

  1310
  Citations

• Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1

  Yue E. Chin;Motoo Kitagawa;Wu Chou S. Su;Zhi Hao You

  1009
  Citations

• Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

  James Chih Hsin Yang;Myung Ju Ahn;Dong Wan Kim;Suresh S. Ramalingam

  558
  Citations

• Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

  Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  522
  Citations

• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial

  James Chih Hsin Yang;Jin Yuan Shih;Wu Chou Su;Te Chun Hsia

  496
  Citations

• Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

  Lecia V. Sequist;Ji Youn Han;Myung Ju Ahn;Byoung Chul Cho

  395
  Citations

• Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia.

  Qing Lan;Chao A. Hsiung;Keitaro Matsuo;Yun Chul Hong

  362
  Citations

• Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.

  Wu Chou S. Su;Motoo Kitagawa;Ninrong Xue;Bing Xie

  354
  Citations

• Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

  Yi Long Wu;Li Zhang;Dong Wan Kim;Xiaoqing Liu

  334
  Citations

• Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

  H. H. Yeh;Wu-Wei Lai;Helen H.W Chen;Hsiao-Sheng Liu

  320
  Citations

• Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non–Small Cell Lung Cancer

  Helen H.W. Chen;Nan Tsing Chiu;Wu Chou Su;How Ran Guo

  312
  Citations

• Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.

  Chao Hua Chiu;Cheng Ta Yang;Jin Yuan Shih;Ming Shyan Huang

  257
  Citations

• Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.

  Roy S. Herbst;Edward B. Garon;Dong Wan Kim;Byoung Chul Cho

  256
  Citations

• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  James Chih-Hsin Yang;Martin H. Schuler;Nobuyuki Yamamoto;Kenneth John O'Byrne

  242
  Citations

• Targeted Paclitaxel by conjugation to iron oxide and gold nanoparticles.

  Jih Ru Hwu;Yu Sern Lin;Thainashmuthu Josephrajan;Ming-Hua Hsu

  240
  Citations